| Trial | control | p<0.05 | harm | NS |
|---|
| Hillestad, 1971 | vs no treatment | | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects ∞ [NaN; ∞] Pro-arrhythmia ∞ [NaN; ∞] Atrial fibrillation recurrence 0.74 [0.48; 1.15] |
| Hohnloser, 1995 | vs no treatment | | Withdrawals due to adverse effects 10.00 [1.38; 72.39] | all cause mortality NaN [NaN; NaN] Pro-arrhythmia 3.00 [0.33; 26.92] Atrial fibrillation recurrence 0.58 [0.28; 1.23] |
| Juul-Moller, 1990 | vs no treatment | | Withdrawals due to adverse effects 2.31 [1.19; 4.47] | all cause mortality 1.15 [0.07; 18.15] Pro-arrhythmia 1.15 [0.07; 18.15] Atrial fibrillation recurrence 1.13 [0.87; 1.47] |
| Kalusche, 1994 | vs no treatment | | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects 2.33 [0.65; 8.40] Pro-arrhythmia 0.50 [0.05; 5.30] Atrial fibrillation recurrence 0.71 [0.43; 1.18] |
| Lloyd (quinidine vs placebo), 1984 | vs no treatment | | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects ∞ [NaN; ∞] Pro-arrhythmia ∞ [NaN; ∞] Atrial fibrillation recurrence 0.84 [0.55; 1.28] |
| PAFAC (quinidine vs placebo), 2004 | vs no treatment | Atrial fibrillation recurrence 0.78 [0.69; 0.88] | | all cause mortality 1.05 [0.23; 4.78] Withdrawals due to adverse effects 1.10 [0.72; 1.68] Pro-arrhythmia 1.98 [0.47; 8.43] |
| SOCESP, 1999 | vs no treatment | | | all cause mortality 0.00 [0.00; NaN] Withdrawals due to adverse effects 1.32 [0.54; 3.23] Pro-arrhythmia 0.61 [0.11; 3.54] Atrial fibrillation recurrence 1.15 [0.72; 1.84] |
| SOPAT (quinidine vs placebo), 2004 | vs no treatment | Withdrawals due to adverse effects 0.74 [0.55; 1.00] Atrial fibrillation recurrence 0.89 [0.82; 0.96] | | all cause mortality ∞ [NaN; ∞] Pro-arrhythmia 1.29 [0.35; 4.83] |
| Sodermark, 1975 | vs no treatment | Atrial fibrillation recurrence 0.73 [0.58; 0.92] | Withdrawals due to adverse effects 5.68 [1.78; 18.14] | all cause mortality 2.05 [0.42; 9.86] Pro-arrhythmia ∞ [NaN; ∞] |
| Steinbeck (quinidine vs digoxin), 1988 | vs no treatment | | | all cause mortality NaN [NaN; NaN] Withdrawals due to adverse effects ∞ [NaN; ∞] Pro-arrhythmia 2.00 [0.20; 19.78] Atrial fibrillation recurrence 0.77 [0.51; 1.16] |
| Byrne Quinn, 1979 | vs no treatment | Atrial fibrillation recurrence 0.79 [0.64; 0.97] | | all cause mortality ∞ [NaN; ∞] Withdrawals due to adverse effects 1.46 [0.67; 3.16] Pro-arrhythmia ∞ [NaN; ∞] |
| Steinbeck (quinidine vs flecainide), 1988 | vs no treatment | | | |
| Lloyd (quinidine vs disopyramide), 1984 | vs no treatment | | | |
| PAFAC (quinidine vs sotalol), 2004 | vs no treatment | | | |
| SOPAT (quinidine vs sotalol), 2004 | vs no treatment | | | |
| Trial | Treatments | Patients | Method |
|---|
| Hillestad, 1971 | (n=-9) vs. (n=-9) | | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
| Hohnloser, 1995 | Quinidine 1 g/d (n=25) vs. sotalol 240-320 mg/dt (n=25) | Persistent AF between 2 days and 6 months | open Parallel groups Sample size: 25/25 Primary endpoint: FU duration: 6 months |
| Juul-Moller, 1990 | Quinidine 1,2 g/d (n=85) vs. Sotalol 160-320 mg/dt (n=98) | Persistent AF between 2 months and 1 year | open Parallel groups Sample size: 85/98 Primary endpoint: FU duration: 6 months |
| Kalusche, 1994 | Quinidine 1 g/d (n=41) vs. Sotalol 240-400 mg/dt (n=41) | AF lasting from 2 weeks to 2 years | open Parallel groups Sample size: 41/41 Primary endpoint: FU duration: 12 months |
| Lloyd (quinidine vs placebo), 1984 | quinidine 1.4 g/d (n=-9) vs. placebo (n=25) | Persistent AF lasting 1 month to 3 years | double blind Parallel groups Sample size: -9/25 Primary endpoint: FU duration: 6 months |
| PAFAC (quinidine vs placebo), 2004 | Quinidine 0,480 g/d (+ verapamil (n=377) vs. placebo (n=88) | Persistent AF lasting > 7 daysil | double blind Parallel groups Sample size: 377/88 Primary endpoint: FU duration: 12 months |
| SOCESP, 1999 | Quinidine 700 mg/d (n=63) vs. sotalol 240 mg/d (n=58) | AF lasting < 6 months | open Parallel groups Sample size: 63/58 Primary endpoint: FU duration: 6 months |
| SOPAT (quinidine vs placebo), 2004 | Quinidine 0,320 or 0,480 g/d (+ verapamil) (n=518) vs. placebo (n=251) | Paroxysmal AF documented in the last 1 month@4 | double blind Parallel groups Sample size: 518/251 Primary endpoint: FU duration: 12 months |
| Sodermark, 1975 | Quinidine 1.2 - 1.8 g/d (n=110) vs. no treatment (n=75) | Persistent AF or AFl lasting < 3 year | open Parallel groups Sample size: 110/75 Primary endpoint: FU duration: 12 months |
| Steinbeck (quinidine vs digoxin), 1988 | Quinidine 1 g/d (+ digoxine) (n=15) vs. digoxine alone (n=15) | Paroxysmal symptomatic AF of any duration | open Parallel groups Sample size: 15/15 Primary endpoint: FU duration: 12 months |
| Byrne Quinn, 1979 | Quinidine 1.2 g/d (n=32) vs. placebo (n=42) | Persistent AF | double blind Parallel groups Sample size: 32/42 Primary endpoint: FU duration: 12 months |
| Steinbeck (quinidine vs flecainide), 1988 | Quinidine 1 g/d (+ digoxine)
, Quinidine 1 g/d (+ digoxine)
(n=15) vs. (n=15)
| Paroxysmal symptomatic AF of any duration
| open Parallel groups Sample size: 15/15 Primary endpoint: FU duration: 12 months
|
| Lloyd (quinidine vs disopyramide), 1984 | quinidine 1.4 g/d
, quinidine 1.4 g/d
(n=28) vs. (n=29)
| Persistent AF lasting 1 month to 3 years
| double blind Parallel groups Sample size: 28/29 Primary endpoint: FU duration: 6 months
|
| PAFAC (quinidine vs sotalol), 2004 | Quinidine 0,480 g/d (+ verapamil
, Quinidine 0,480 g/d (+ verapamil
(n=377) vs. (n=383)
| Persistent AF lasting > 7 daysil
| double blind Parallel groups Sample size: 377/383 Primary endpoint: FU duration: 12 months
|
| SOPAT (quinidine vs sotalol), 2004 | Quinidine 0,320 or 0,480 g/d (+ verapamil)
, Quinidine 0,320 or 0,480 g/d (+ verapamil)
(n=518) vs. (n=264)
| Paroxysmal AF documented in the last 1 month@4
| double blind Parallel groups Sample size: 518/264 Primary endpoint: FU duration: 12 months
|
